Recombinant DNA Technology Market - By Types (Expression System and Cloning Vector), By Product (Medical and Non-Medical), By Application (Diseases, Plants, and Others), and By End User (Research Institutes, Biotechnology Companies, and Pharmaceuticals) -

Recombinant DNA Technology Market - By Types (Expression System and Cloning Vector), By Product (Medical and Non-Medical), By Application (Diseases, Plants, and Others), and By End User (Research Institutes, Biotechnology Companies, and Pharmaceuticals) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022 - 2028

Report Description
Recombinant DNA technology has allowed the transfer of desired characteristics which is useful to improve the existing systems by controlling expression of target genes. Recombinant DNA technology allows mass production of therapeutic proteins, which are characterized by high level of consistency and stability. The technology has multidisciplinary applications and potential to deal with important aspects of life, for instance, improving health, and enhancing food resources. The genetically modified plants have augmented resistance to viruses and insect attacks, enhanced product yield, and shown increased adaptability for better survival.
Market Dynamics
Rapid technological advancements in the field of genetic engineering to deliver highly efficient therapeutics for disease management and in the field of agriculture are major driving factors for growth of recombinant DNA technology market. For instance, Bac-to-Bac Baculovirus Expression Systems offers a quick and efficient method to produce recombinant baculovirus and can express the desired genes in insect cells and provide high yields of recombinant protein that speeds up the cloning reaction as compared to the time-consuming restriction enzyme cloning, which takes 2–3 days. Also, in 2021, a BioAg Alliance was formed between Monsanto and Novozymes A/S, to improve crop harvests by using products containing naturally-occurring microbes to boost agricultural productivity and expand its product portfolio. However, the adoption of non-biologic therapeutics and higher complexity of the genetically engineered products such as stability of the cell lines, requirement of skilled professionals, and optimum temperature are the factors hindering the market growth.
Key features of the study:
This report provides in-depth analysis of recombinant DNA technology market and provides market size (US$ Billion) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global recombinant DNA technology market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include Thermo Fisher Scientific, Inc., Biogen, Inc., Sanofi Pasteur, Merck & Co., Inc., Pfizer, Inc., Profacgen, Amgen, Inc., and Monsanto Company
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global recombinant DNA technology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the recombinant DNA technology market
Detailed Segmentation:
Global Recombinant DNA Technology Market, By Product Type:
Recombinant Protein Drugs
Insulin
Human Growth Hormone
Erythropoietin
Interferon
Blood Factors
Colony Stimulating Factors
Fusion Proteins
Others
Vaccines
Genetically Modified Crops
Expression Systems
Prokaryotic Cells
Mammalian Cells
Yeats
Insect
Others
Cell and Gene Therapy
Gene Editing
Global Recombinant DNA Technology Market, By Application:
Therapeutics
Agriculture
Research
Global Recombinant DNA Technology Market, By Geography:
North America
By Product Type:
Recombinant Protein Drugs
Insulin
Human Growth Hormone
Erythropoietin
Interferon
Blood Factors
Colony Stimulating Factors
Fusion Proteins
Others
Vaccines
Genetically Modified Crops
Expression Systems
Prokaryotic Cells
Mammalian Cells
Yeats
Insect
Others
Cell and Gene Therapy
Gene Editing
By Application:
Therapeutics
Agriculture
Research
By Country:
U.S.
Canada
Latin America
By Product Type:
Recombinant Protein Drugs
Insulin
Human Growth Hormone
Erythropoietin
Interferon
Blood Factors
Colony Stimulating Factors
Fusion Proteins
Others
Vaccines
Genetically Modified Crops
Expression Systems
Prokaryotic Cells
Mammalian Cells
Yeats
Insect
Others
Cell and Gene Therapy
Gene Editing
By Application:
Therapeutics
Agriculture
Research
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type:
Recombinant Protein Drugs
Insulin
Human Growth Hormone
Erythropoietin
Interferon
Blood Factors
Colony Stimulating Factors
Fusion Proteins
Others
Vaccines
Genetically Modified Crops
Expression Systems
Prokaryotic Cells
Mammalian Cells
Yeats
Insect
Others
Cell and Gene Therapy
Gene Editing
By Application:
Therapeutics
Agriculture
Research
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Product Type:
Recombinant Protein Drugs
Insulin
Human Growth Hormone
Erythropoietin
Interferon
Blood Factors
Colony Stimulating Factors
Fusion Proteins
Others
Vaccines
Genetically Modified Crops
Expression Systems
Prokaryotic Cells
Mammalian Cells
Yeats
Insect
Others
Cell and Gene Therapy
Gene Editing
By Application:
Therapeutics
Agriculture
Research
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product Type:
Recombinant Protein Drugs
Insulin
Human Growth Hormone
Erythropoietin
Interferon
Blood Factors
Colony Stimulating Factors
Fusion Proteins
Others
Vaccines
Genetically Modified Crops
Expression Systems
Prokaryotic Cells
Mammalian Cells
Yeats
Insect
Others
Cell and Gene Therapy
Gene Editing
By Application:
Therapeutics
Agriculture
Research
By Country:
GCC
Israel
Rest of Middle East
Africa
By Product Type:
Recombinant Protein Drugs
Insulin
Human Growth Hormone
Erythropoietin
Interferon
Blood Factors
Colony Stimulating Factors
Fusion Proteins
Others
Vaccines
Genetically Modified Crops
Expression Systems
Prokaryotic Cells
Mammalian Cells
Yeats
Insect
Others
Cell and Gene Therapy
Gene Editing
By Application:
Therapeutics
Agriculture
Research
By Country:
South Africa
Central Africa
North Africa
Company Profiles
Thermo Fisher Scientific, Inc.*
Company Overview
Product Portfolio
Key Developments
Financial Overview
Market Strategies
Biogen, Inc.
Sanofi Pasteur
Merck & Co., Inc.
Pfizer, Inc.
Profacgen
Amgen, Inc.
Monsanto Company
“*” marked represents similar segmentation in other categories in the respective section.